The company’s products are based on caprotec’s proprietary Capture Compound Mass Spectrometry (CCMS) technology, a novel and direct way to investigate small molecule - protein interactions resulting in a significant functional reduction of proteome complexity. Capture Compounds enable the direct isolation and identification of selected proteins, including membrane proteins, out of any complex biological sample and are available as ready to use caproKits™.
“To establish a distribution channel for our products into the Japanese market is of strategic importance to us. We believe that our innovative and high quality research products will serve the Japanese researchers well,” stated Dr. Hubert Köster, CEO of caprotec bioanalytics.
Dr. Ryoya Funakoshi, President & CEO of Funakoshi Co., Ltd. stated, "We are delighted with this distribution agreement. caprotec’s proprietary and patented technology, known as CCMS, perfectly complements our range of top quality products and services, and will enable us to meet the high demand for proteasome and bimolecular interaction research in Japan."
Dr. Köster continued, “We are very pleased to partner with Funakoshi. Funakoshi has a longstanding expertise and track record in distributing life science products to highly distinguished Japanese research institutions. We see this partnership as a first step in the execution of our program to continuously develop and grow the global distribution channels for caprotec’s products and services. ”
About caprotec bioanalytics GmbH
caprotec bioanalytics GmbH is a Berlin-based biotech company focusing on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called capture compounds (CCs). They enable a targeted isolation of proteins directly from complex biological samples. After isolation the captured proteins are identified and characterized by mass spectrometry. Providing a state-of-the-art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of biomarkers. The technology is protected by a broad patent portfolio.
caprotec bioanalytics was founded in 2006 by Prof. Dr. Hubert Köster, a long-experienced innovator and serial entrepreneur in the field of biotech. His track records include the foundation of Biosyntech, the first biotech company in Germany, the co-foundation of Milligen/Biosearch and the foundation of Sequenom Inc. As CEO and President of Sequenom he was responsible for one of the most successful US biotech IPOs at the NASDAQ.
After closing a financing round of EUR 6 million caprotec bioanalytics started operations in January 2008 in Berlin-Adlershof. The company is supported by an international scientific advisory board including one Nobel Laureate. About Funakoshi Co., Ltd.
Funakoshi Co., Ltd. has been contributing as a leader to distribute research reagents and instruments for researchers in life science fields since its establishment of new business division more than four decades ago.
The mission of Funakoshi is offering many useful tools with leading edge technologies for Japanese researchers from all over the world to support and develop their research.
Additional information is available on the Company's website at www.funakoshi.co.jp.
